Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge is advising Vimian Group AB (publ) (“Vimian”) and the principal shareholder Fidelio Capital AB (“Fidelio”) in connection with a private placement and subsequent listing on Nasdaq First North Growth Market with first day of trading on 18 June 2021
Mandate

Vinge is advising Vimian Group AB (publ) (“Vimian”) and the principal shareholder Fidelio Capital AB (“Fidelio”) in connection with a private placement and subsequent listing on Nasdaq First North Growth Market with first day of trading on 18 June 2021

June 18, 2021 Banking and Finance M&A

Vinge is advising Vimian and the principal shareholder Fidelio in connection with a private placement and subsequent listing on Nasdaq First North Growth Market with first day of trading on 18 June 2021, and also with the reorganization preceding the listing. The price in the private placement values Vimian to c. SEK 29.6 billion.

The Vinge team primarily consists of Jonas Bergström, Dain Hård Nevonen, Linnéa Sellström, Johanna Wiberg, Hanna Risberg, Anders Sundin Lundberg, Matthias Pannier, Stina Bengtsson, Manne Bergström, Annika Nyberg Ekenberg, Benjamin Vafaeian, Amanda Steen and Annie Fällström. Albert Wållgren, Linn Adelwald, Josefine Lanker, Seyran Sahin,  Felix Möller, Caroline Krassén and  Lave White advises on financing matters and VDR assistant Nathalie Hughes .

Related

Vinge advised Precise Biometrics

 Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

 Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026